NCT01495338View on ClinicalTrials.gov

A Comparison of the Safety and Comfort of AC-170

PHASE1CompletedINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions
Normal Ocular Health
Interventions
DRUG

AC-170 0.17%

1 drop in one eye at one timepoint

DRUG

AC-170 0.24% (Formulation 1)

1 drop in one eye at one timepoint

DRUG

AC-170 0.24% (Formulation 2)

1 drop in one eye at one timepoint

DRUG

Olopatadine hydrochloride 0.2%/Tears Naturale II

1 drop in one eye at one timepoint

Trial Locations (1)

01810

Andover Eye Associates, Andover

Sponsors
All Listed Sponsors
lead

Aciex Therapeutics, Inc.

INDUSTRY

NCT01495338 - A Comparison of the Safety and Comfort of AC-170 | Biotech Hunter | Biotech Hunter